Voyager Acquisition Corp
NASDAQ: VRXAW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christoph Antz
- Headquarters
- Zürich, Switzerland
- IPO year
- 2026
- Market cap
- $2.8M
- Website
- https://www.veraxa.com
Loading VRXAW…
Loading profile data…Frequently asked questions about VRXAW
What does Voyager Acquisition Corp (VRXAW) do?
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Labo...
Where does VRXAW trade?
Voyager Acquisition Corp (VRXAW) trades on the NASDAQ Global Market.
What sector is VRXAW in?
Voyager Acquisition Corp (VRXAW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Voyager Acquisition Corp?
Christoph Antz is the chief executive officer of Voyager Acquisition Corp (VRXAW).
Where is Voyager Acquisition Corp headquartered?
Voyager Acquisition Corp is headquartered in Switzerland.
Does VRXAW pay a dividend?
Voyager Acquisition Corp (VRXAW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VRXAW go public?
Voyager Acquisition Corp (VRXAW) completed its initial public offering in 2026.